The company is substantially advanced this course of an novel treatment for amyloid heart disease, leveraging the compound. Early trial data indicates promising outcomes for patients diagnosed by this severe disease. The focus represents researchers’ commitment to managing significant patient needs in this cardiology arena. Attruby: BridgeBio's